This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

This indicator includes the count and rate of newly diagnosed cases of Hepatitis C per 1,000 individuals estimated to have Drug Use Disorder.

Statewide rates of newborn hospital stays with Neonatal Abstinence Syndrome (NAS) per 1,000 newborn stays.
Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent.
This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.
PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

The county aggregate number of individuals on Medicaid who have filled a Naloxone Prescription. This includes all individuals on Medicaid. Naloxone is an opioid antagonist. It acts on the CNS to block the effects of narcotics, especially the "high'' feeling that makes you want to use them. It will not produce any narcotic-like effects or cause mental or physical dependence. Numbers are for the Calendar Year.

This indicator includes the rate of hospitalization per 1,000 individuals estimated to have Opioid Use Disorder (OUD) for Opioid Use Disorder, Intracranial and intraspinal Abscess, Osteomyelitis, Endocarditis, Soft skin tissue infection, and Viral Hepatitis (B, C, and D) for individuals diagnosed with OUD in the same calendar year.
Analyses were completed by the University of Pittsburgh using data from the PA Health Care Cost Containment Council and in cooperation with PA DOH.
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.

This dataset summarizes the number of women (12 to 55 years old) with a delivery—live birth or stillbirth— in 2017 or 2018 and indicates how many of those women were diagnosed with opioid use disorder (OUD) during their pregnancy.

Analyses were completed by the University of Pittsburgh using data from the PA Health Care Cost Containment Council and in cooperation with PA DOH.
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.

Percent of Pennsylvania newborn hospital stays, categorized by the presence or absence of Neonatal Abstinence Syndrome (NAS), with Medicaid as the Anticipated Primary Payer.
Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent.
This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.
PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

This dataset summarizes the number of live births in 2016 or 2017 and indicates how many of those neonates or newborns on Medical Assistance (MA) were diagnosed in their first 90 days of life with withdrawal symptoms or otherwise affected from maternal use of drugs of addiction.

This indicator includes the count and rate of newly diagnosed cases of HIV through injection drug use per 100,000 individuals estimated to have Drug Use Disorder. It also provides a reference line by year of new HIV diagnoses among individuals using injection drugs. This allows viewing of the trend between all new HIV diagnoses and HIV diagnoses among individuals using injection drugs.

This dataset summarizes the number of women (12 to 55 years old) with a delivery—live birth or stillbirth— in 2017 or 2018 and indicates how many of those women were diagnosed with opioid use disorder (OUD) during their pregnancy.